Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - desferrioxamine mesilate, quantity: 500 mg - injection, powder for - excipient ingredients: water for injections - a) acute iron intoxication. b) chronic iron overload due to transfusion-dependent anemias. c) diagnosis of aluminium overload (desferrioxamine infusion test). d) chronic aluminium overload in patients with esrf under maintenance dialysis. in cases of acute iron intoxication, desferrioxamine is an adjunct to, and not a substitute for, standard therapeutic measures whuich may include: i) induction of emesis. ii) gastric lavage. iii) maintenance of clear airways. iv) control of peripheral vascular failure. v) correction of acidosis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - carboplatin injection is indicated for the treatment of ovarian cancer and small cell lung carcinoma.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - carboplatin is indicated in the treatment of extensive carcinoma of the ovary (originally epithelial), by way of initial treatment or by way of second treatment line when other therapeutic means have failed. carboplatin is also indicated in treatment of carcinoma in small-cell and non-small-cell of the lung and in carcinoma of epidermis of the head and the neck. significant responses were also observed when the carboplatin was used in the treatment of carcinoma of the uterine collar.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in the treatment of acute leukemia. it has also been used in combination with other antineoplastic drugs in hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of uterine cervix, malignant melanoma, colorectal cancer, non-hodgkin's lymphoma, and wilm's tumor.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - erythromycin -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection - excipient ingredients: lactose monohydrate - epirubicin hypdrochloride for injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - mitoxantrone (mitozantrone) hydrochloride, quantity: 2.33 mg/ml (equivalent: mitoxantrone, qty 2 mg/ml) - injection - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite - mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mitoxantrone in combination with other approved drus(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (anll) in adults. this category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.